Prospective Post Approval Clinical Follow-Up Study of the Commercially Available U2 Knee™ System - "U-Propel Study"
Status: | Recruiting |
---|---|
Conditions: | Osteoarthritis (OA) |
Therapuetic Areas: | Rheumatology |
Healthy: | No |
Age Range: | 18 - 75 |
Updated: | 5/4/2018 |
Start Date: | March 30, 2017 |
End Date: | March 30, 2024 |
Contact: | Mindy Carlson |
Email: | mindy.carlson@uocusa.com |
Phone: | 612-562-0060 |
The purpose of this study is to evaluate both short and long term clinical performance and
safety of the commercially available U2 Knee™ System.
safety of the commercially available U2 Knee™ System.
This is a prospective, single arm, multi-center, post-approval study designed to evaluate the
short and long term clinical performance and safety in subjects receiving primary total knee
arthroplasty (TKA) with the U2 Knee™ System. The study will enroll up to 200 subjects with
scheduled pre-discharge, 6-week, 3- and 6-month and up to 5-year annual follow-up visits.
Study outcomes will be analyzed and published when 1.) all enrolled and implanted subjects
complete their 6-week follow up, 2.) all implanted subjects complete their 2-year follow up,
3.) at the conclusion of the study.
The study will follow GCP guidelines and will be registered on clinicaltrials.gov.
short and long term clinical performance and safety in subjects receiving primary total knee
arthroplasty (TKA) with the U2 Knee™ System. The study will enroll up to 200 subjects with
scheduled pre-discharge, 6-week, 3- and 6-month and up to 5-year annual follow-up visits.
Study outcomes will be analyzed and published when 1.) all enrolled and implanted subjects
complete their 6-week follow up, 2.) all implanted subjects complete their 2-year follow up,
3.) at the conclusion of the study.
The study will follow GCP guidelines and will be registered on clinicaltrials.gov.
Inclusion Criteria:
1. Subject is between 18 and 75 years of age
2. Subject is indicated for a unilateral total knee arthroplasty (TKA) based on the
approved labeling of the device
3. Subject has no history of previous prosthetic replacement device or orthopedic
surgeries on the operative knee
4. Subject is willing and able to provide informed consent to participate in the study;
5. Subject is willing and able to understand the purpose of the study, his/her role, and
is available to return to the clinic/hospital for all required follow-up visits;
Exclusion Criteria:
- Subjects will be excluded if, in the opinion of the Investigator, the subject does not
qualify based on approved labeling requirements or Subject Inclusion criteria.
We found this trial at
4
sites
6015 Pointe West Boulevard West
Bradenton, Florida 34209
Bradenton, Florida 34209
Principal Investigator: David Cashen, MD
Phone: 941-782-1353
Click here to add this to my saved trials
2401 West Belvedere Avenue
Baltimore, Maryland 21215
Baltimore, Maryland 21215
Phone: 410-601-8500
Click here to add this to my saved trials
2 Shircliff Way
Jacksonville, Florida 32204
Jacksonville, Florida 32204
Principal Investigator: Stanton Longenecker, MD
Phone: 904-388-1400
Click here to add this to my saved trials
Vero Beach, Florida 32960
Principal Investigator: Richard Steinfeld, MD
Phone: 772-778-2009
Click here to add this to my saved trials